HAL
open science

Metabolic reprogramming: an innate cellular defence mechanism against intracellular bacteria?

Pedro Escoll, Carmen Buchrieser

To cite this version:

Pedro Escoll, Carmen Buchrieser. Metabolic reprogramming: an innate cellular defence mechanism against intracellular bacteria?. Current Opinion in Immunology, 2019, Host pathogens, 60, pp.117-123. 10.1016/j.coi.2019.05.009 . pasteur-02880718

HAL Id: pasteur-02880718

https://pasteur.hal.science/pasteur-02880718v1

Submitted on 25 Jun 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Metabolic reprogramming: an innate cellular defense mechanism against intracellular bacteria?

Pedro Escoll[1]* & Carmen Buchrieser[1]*

[1]*Institut Pasteur, Biologie des Bactéries Intracellulaires, UMR 3525, CNRS, Paris, France*

Short title: Immunometabolism and intracellular bacteria

Key words: Intracellular bacteria, metabolism, innate immune cells, host-pathogen inetractions

*For correspondence:

Pedro Escoll and Carmen Buchrieser
Institut Pasteur, Biologie des Bactéries Intracellulaires
28, rue du Dr. Roux, 75724 Paris Cedex 15, France
Tel: (33-1)-45-68-83-72
Fax: (33-1)-45-68-87-86
E-mail: *pescoll@pasteur.fr* and *cbuch@pasteur.fr*

Abstract

The limited metabolic resources of a cell represent an intriguing "conflict of interest" during host-pathogen interactions, as the battle for nutrients might determine the outcome of an infection. To adapt their metabolic needs, innate immune cells such as monocytes, macrophages or dendritic cells reprogram their metabolism upon activation by microbial compounds. In turn, infection by intracellular bacteria provokes metabolic alterations of the host cell that benefit the pathogen. Here we discuss the state-of-the-art knowledge on metabolic reprogramming of host cells upon activation or infection with intracellular bacteria. The study of the host- and pathogen-driven metabolic alterations that seem to co-exist during infection is an emerging field that will define the metabolic pathways that might be targeted to combat infection.

Introduction

Cellular metabolism comprises the controlled biochemical processes that occur within a cell to maintain life. It is generally divided in, anabolic processes (the build-up of macromolecules) and catabolic processes (the breakdown of macromolecules). To maintain constant cellular conditions in response to changes in the environment (homeostasis) a cell regulates its specific needs by the fine-tuning of these metabolic pathways.

During host-pathogen interactions, host and pathogen fight for the nutrients needed for cellular catabolism, as resources are generally limited [1,2]. Obtaining energy and ready-to-use basic molecules is key to build up new cellular components, to grow and reproduce, or to respond to environmental changes. Thus the result of this metabolic clash is key for the outcome of host-pathogen interactions and the infection process.

Cellular metabolism is one of the most complex and intricate cellular systems. To simplify, two main catabolic programs work to obtain energy, "glycolysis" and "oxidative phosphorylation" (OXPHOS) (Figure 1A). During glycolysis that is performed in the cytosol, cells convert glucose into pyruvate by anaerobic glycolysis and then pyruvate is fermented to lactate. Thereby 2 ATP molecules are generated per molecule of glucose. During OXPHOS the pyruvate generated by anaerobic glycolysis is routed to mitochondria where it is oxidized to CO_2 via the tricarboxylic acid (TCA) cycle. The released energy (stored as NADH) is used by the electron transport chain (ETC) to pump protons across the membrane. This generates an electrochemical gradient used to synthesize ATP by the mitochondrial F_1-F_O-ATPase. Under the OXPHOS program, the cell produces 36 ATPs per molecule of glucose [3].

Interestingly, many proliferating cells (such as embryonic stem cells, cancer cells or activated T-cells) prefer the glycolytic program although this metabolic pathway is less efficient for ATP production as compared to OXPHOS. In contrast, tumour cells convert most of the absorbed glucose to lactate even under oxygen-rich conditions, a program that was termed "aerobic glycolysis" or the "Warburg effect" (Figure 1B) [4]. Thus elevated glucose uptake and lactate secretion are metabolic hallmarks of solid tumours [5,6]. Although the question why cancer cells prefer a "less efficient" metabolic pathway to grow is still a matter of debate, it seems that aerobic glycolysis coupled to fermentation is a fast process, easy to regulate, that fulfils all metabolic requirements of a proliferating cell. The Warburg program maximizes biosynthetic pathways by redirecting cytosolic glycolysis and the mitochondrial TCA cycle to the biosynthesis of nucleotides, amino acids and lipids (Figure 1B). The fast withdrawal of pyruvate and TCA intermediates in the mitochondria, which are normally

dedicated to the OXPHOS program and their redirection to biosynthetic pathways, explains the reduction of oxygen consumption after the switch to the Warburg metabolism. Thus Warburg metabolism seems to be induced to reprogram cellular metabolism towards macromolecular synthesis.

Reprogramming to Warburg-like metabolism has been observed during activation of diverse immune cells and, interestingly, also during infection of human cells by intracellular bacterial pathogens such as *Mycobacterium tuberculosis* [7-11], *Legionella pneumophila* [12], *Brucella abortus* [13], *Chlamydia trachomatis* [14,15] or *C. pneumoniae* [16]. Although the Warburg program in proliferating T-cells and cancer cells can be seen as program necessary for proliferation, the induction of the Warburg program in infected cells raises intriguing questions. Why non-proliferating immune cells, such as monocytes, dendritic cells (DCs) or macrophages, switch to a Warburg-like metabolism during infection? What is the impact of such metabolic changes on the pathogen that obtains its nutrients only from the infected host cell? Is metabolic reprogramming beneficial or detrimental for intracellular bacteria? Are these metabolic alterations driven by the host cell itself in response to bacteria, as a defence mechanism, or are they induced by the pathogen for its own benefit?

Non-proliferating immune cells reprogram metabolic pathways upon stimulation with microbial compounds

Monocytes, DCs and macrophages are differentiated, non-proliferative, innate immune cells that, once activated by microbial stimuli, orchestrate the activation of other immune cells through the secretion of immuno-regulatory cytokines, but they also increase glycolytic fluxes and modulate their metabolism.

In DCs, glucose uptake is increased and accompanied by lactate production shortly after their activation by microbial compounds that engage Toll-like receptors (TLRs) such as bacterial lipoplysacharide (LPS). After TLR stimulation, a signalling cascade involving TBK1, IKK□ and Akt promotes the association of the glycolytic enzyme hexokinase-2 (HK2) with mitochondria increasing its enzymatic activity and therefore the glycolytic flux, however, cellular ATP is still provided by OXPHOS [17]. At these early time points, glycolysis supplies DCs with citrate, which fuels the synthesis of fatty acids that are required by activated DCs to increase the size of the endoplasmic reticulum (ER) and the Golgi apparatus [17]. Thus, the fast and early metabolic switch of DCs to a glycolytic program due to the stimulation with microbial compounds is linked to fatty acid synthesis and the adoption of the

secretory state. At 24 h of DC activation by LPS, iNOS-derived NO inhibits cellular OXPHOS, which almost disappears and DCs rely exclusively on glycolysis, a Warburg-like metabolic program is installed [18].

In murine bone-marrow-derived macrophages (BMDMs), metabolic reprogramming to a glycolytic Warburg-like program is necessary for transcription of the pro-inflammatory cytokine IL1β. Upon LPS stimulation, BMDMs show a broken TCA cycle and intermediates, such as succinate or citrate, accumulate [19]. Furthermore, LPS induces the up-regulation of pyruvate kinase M2 (PKM2) dimer and tetramer levels. In its enzymatically inactive form (dimers), increased PKM2 induces succinate accumulation [20]. PKM2 dimers also migrate to the nucleus where they induce PKM2-mediated transcription of IL1β. In its enzymatically active form (tetramers), LPS-induction of PKM2 also increases the rate of glycolytic fluxes, as the reaction catalysed by PKM2 is the rate-limiting step of glycolysis. Accumulated succinate stabilizes HIF1α, which can now translocate to the nucleus and, together with PKM2 dimers, drive IL1β gene expression. Succinate in mitochondria is oxidized by succinate dehydrogenase and leads to the reverse flow of the ETC, which produces mitochondrial reactive oxygen species (mROS) that also induce HIF1α-mediated IL1β mRNA expression [21]. Accumulation of citrate is due to the LPS-induced expression of the mitochondrial citrate carrier, which diverts citrate from the mitochondrial TCA cycle to the cytoplasm. Cytoplasmic citrate is then used to generate NO, ROS and prostaglandins by BMDMs, as well as to produce the antimicrobial metabolite itaconate [22-24].

Taken together, exposure of murine macrophages to bacterial LPS reprograms their metabolism from OXPHOS to glycolysis, rewiring TCA intermediates such as citrate and succinate to biosynthetic pathways. As itaconate has direct antimicrobial proprieties against a wide range of intracellular bacteria, such as *M. tuberculosis*, *Salmonella enterica* or *L. pneumophila* [25], the redirection of citrate for the synthesis of itaconate represents a prominent example of how metabolic reprogramming of activated macrophages becomes a defence mechanism against infection by intracellular bacteria. In addition to its antibacterial proprieties, itaconate has also immunoregulatory functions during infection due to its inhibitory actions on the production of mROS and certain cytokines and chemokines as shown for BMDMs infected with *S. enterica* serovar Typhimurium [26], and for mice infected with *M. tuberculosis* [27].

Recently it was shown that human monocytes isolated from blood also shift to a Warburg-like metabolism when stimulated with LPS, but not upon stimulation with the TLR2 ligand

145 Pam3Cys (P3C) or whole-pathogen lysates. Indeed, in P3C stimulated monocytes, increased
146 glycolysis was accompanied by increased OXPHOS, which was required for retention of their
147 phagocytic capacity and cytokine production [28]. Elevated succinate, itaconate and citrate
148 levels were only observed in LPS-stimulated monocytes, but not in P3C-stimulated
149 monocytes. Interestingly, exposure of human monocytes to *M. tuberculosis* whole cell lysates
150 did not affect OXPHOS, in contrast to infection of monocytes with living *M. tuberculosis* or
151 after exposure to LPS as OXPHOS reduction was observed [9,28]. Moreover, exposure of
152 monocytes to *Escherichia coli* or *Staphylococcus aureus* whole-cell lysates leads to increased
153 OXPHOS [28], suggesting that heterogeneous metabolic responses may be elicited depending
154 on the specific pathogen and TLR activation pattern involved.

155 These results indicate that metabolic reprogramming of innate immune cells upon
156 stimulation with microbial components rewires cellular metabolism to biosynthetic pathways
157 that drive growth of cell size and production and secretion of cytokines and antimicrobial
158 compounds. It is critical to clarify whether these metabolic alterations are stimuli-specific
159 (LPS *vs.* P3C), cell-type specific (macrophages *vs.* monocytes *vs.* DCs), host-species specific
160 (mouse *vs.* human) and/or bacterial-species specific (*S. aureus vs. M. tuberculosis*).
161

162 **Intracellular bacteria reprogram the host metabolism to a Warburg-like metabolism**

163 *M. tuberculosis* [7-11], *L. pneumophila* [12], *B. abortus* [13], *C. trachomatis* [14,15],
164 *C. pneumoniae* [16] or *Listeria monocytogenes* [29,30], were reported to modulate the
165 metabolism of their host cells to a Warburg-like metabolism [31]. Yet only few studies
166 addressed the metabolism of primary cells during infection thus one must be careful with the
167 interpretation of metabolic changes as most cancer cell lines have an enhanced Warburg
168 metabolism due to their tumour origin [31]. This has been demonstrated for *L. monocytogenes,*
169 as high induction of glucose uptake and glycolysis was only observed in primary BMDMs,
170 and not in the murine macrophage-like cells line J774A.1. However, intracellular bacteria
171 replicated to five fold higher numbers within the cancer cell line than in primary cells,
172 suggesting that the Warburg metabolism exhibited by cell lines might promote bacterial
173 replication [29].

174 The changes to a Warburg-like metabolism induced by many intracellular bacteria come in
175 different styles (Figure 3). *Chlamydia trachomatis* infection of primary human umbilical vein
176 endothelial cells leads to a specific Warburg-like program. Cellular glucose uptake and the
177 phosphate pentose pathway (PPP), a nucleotide biosynthetic pathway derived from the

178 glycolytic flux are increased [15] (Figure 3A, *Chl*). The infection-dependent upregulation of
179 the PPP supplies the pathogen with nucleotides for intracellular replication, which serve as
180 nutrients together with amino acids, and lipids that *C. trachomatis* needs to sequester from the
181 host cell [32]. Thus, the induction of this Warburg-like program during infection seems to
182 benefit the pathogen.

183 *L. pneumophila* induces a Warburg-like metabolism characterized by the upregulation of
184 glycolysis and reduction of OXPHOS dependent on the injection of the bacterial effector
185 MitF in the host cell that induces reduction of OXPHOS through fragmentation of
186 mitochondrial networks [12]. This metabolic reprogramming of infected cells to a Warburg-
187 like program appears essential for bacterial growth and might be related to the need of amino
188 acids, the main source of energy for growing *L. pneumophila* [3,33], which can be
189 synthesized from redirected glycolytic and/or TCA intermediates (Figure 3B, *Lp*).

190 *M. tuberculosis* infection induces a Warburg-like program when infecting human primary
191 macrophages, that is characterized by decreased OXPHOS and upregulation of glucose uptake
192 and glycolysis coupled with the redirection of glycolytic intermediates to the synthesis of
193 large lipid bodies that accumulate in the macrophage (Figure 3C, *Mtb*). These lipid bodies,
194 together with the lactate produced by glycolysis, serve as nutrients for intracellular growth of
195 the pathogen [34-36], suggesting that the biosynthetic role of the Warburg-like program
196 benefits the intracellular replication of *M. tuberculosis*.

197 Although it is not clear yet whether *Salmonella enterica*, induces a Warburg-like
198 metabolism in the host cells or not, it has been reported that *S. enterica* modulates the
199 metabolism of the cell it infects. During *in vivo* infection of mice with *S. enterica* serovar
200 *typhimurium*OXPHOS is completely shut-off [37], while glycolysis might be induced [38].
201 However, the most prominent metabolic alteration induced by *S. typhimurium* seems the
202 piracy of glucose by the pathogen. In mouse BMDMs *Salmonella* disrupts glycolytic fluxes to
203 reroute glucose from host macrophages to its vacuole (Figure 3A, *St*) and thereby this
204 pathogen reduces host glucose availability [39,40]. Interestingly, inhibition of glycolytic
205 fluxes creates a unique metabolic defect that activates the NLRP3 inflammasome [40].
206

207 **Intracellular bacteria modulate autophagy, a catabolic program and a cellular defense**
208 **system**

209 Another important metabolic response to infection is the cellular process known as
210 autophagy, a self-degradative process that is key for balancing sources of energy in response

211 to nutrient stress and to remove intracellular pathogens in response to infection [41-43].
212 Interestingly, autophagy also regulates cytokine production and secretion in immune cells
213 upon microbial stimulation [44,45].

214 Host-driven and pathogen-driven alterations of autophagy occur during infection with
215 intracellular bacteria. As host-induced autophagy degrades invading pathogens, evasion of
216 autophagy is key for pathogens such as *M. tuberculosis*, *S. typhimurium* or *L. pneumophila*
217 that inhibit autophagy initiation upstream of autophagosome formation, or *Shigella flexneri*
218 that evades autophagy recognition by masking the bacterial surface [46-49]. Interestingly,
219 *L. pneumophila* encodes two secreted effectors, RavZ and LpSPL that inhibit autophagosome
220 formation at two different stages [47,50]. Other intracellular bacteria such as *Anaplasma*
221 *phagocytophilum*, *Yersinia pseudotuberculosis*, *Coxiella burnetii* and *Francisella tularensis*
222 hijack autophagosomes during infection to redirect the by-products of the autophagic
223 degradation of cellular components to their vacuoles for their own nutritional use, which
224 finally promotes bacterial replication [51]. For instance, *A. phagocytophilum* secrets the
225 effector Ats-1 to induce autophagosome formation to obtain nutrients contained in them [52],
226 showing that pathogens may activate autophagy also for their benefit.

227 Taken together, these results suggest that modulation of autophagy during bacterial
228 infection is host- as well as pathogen-driven and leads to alterations of the metabolism and the
229 immune defences of the infected cell.
230

231 **Concluding remarks**

232 Some metabolic host responses, such as activation of the HIF1α axis, commonly occur in
233 macrophages and other cell types upon bacterial infection [53]. However, pathogen specific
234 reprogramming of the cellular metabolism [28] and metabolic alterations triggered by
235 bacterial effectors [12], which seem beneficial for the pathogen, also exist. A recurrent debate
236 is whether the observed metabolic changes in infected cells are host-driven in response to
237 bacterial invasion, or driven by the pathogen to benefit its intracellular survival and
238 replication. As some metabolic alterations such as autophagy modulation or induction of
239 Warburg-like programs, seem dependent on bacterial effectors and beneficial for the pathogen,
240 both processes seem to happen in parallel and thus the observed metabolic phenotypes during
241 infection are a mixture of host-driven and pathogen-driven metabolic reprogramming,
242 reflecting the battle for resources in an infected cell.

Furthermore, some pathogen-mediated metabolic alterations during infection seem to trigger host immune responses. An example is the NLRP3 inflammasome activation following the inhibition of glycolytic fluxes at the level of GAPDH by *S. enterica* [40], or the binding of bacterial sugars to the glycolytic enzyme HK2, a member of the sugar kinase family that binds glucose and surprisingly triggers NLRP3 inflammasome activation when binding bacterial peptidoglycan-derived N-acetylglucosamine [54].

Although many puzzling enigmas remain to be clarified, a novel aspect may emerge from the "immune surveillance hypothesis" [55]. While this hypothesis defends that pathogen-mediated disruption of host physiology leads to immune activation, we think that an additional novel aspect should be added: specific checkpoints might exist along cellular metabolic pathways that, when altered, trigger immune responses such as inflammasome activation. We thus suggest the term *"Danger-Associated Metabolic Modifications"* (DAMMs) for alterations in the metabolism of host cells that trigger defence responses. OXPHOS dysfunction, altered glycolytic fluxes or piracy of metabolic intermediates induced by intracellular bacteria might be DAMMs linking pathogen-driven and host-driven metabolic reprogramming. Future work should shed light on these exciting and complex host-pathogen interactions.

Declarations of interest: none.

Acknowledgments

This work was supported by the Institut Pasteur and the Agence National de Recherche [grant number ANR-10-LABX-62-IBEID].

268 **References**

269 1. Eisenreich W, Rudel T, Heesemann J, Goebel W: **To Eat and to Be Eaten: Mutual**
270 **Metabolic Adaptations of Immune Cells and Intracellular Bacterial Pathogens**
271 **upon Infection**. *Front Cell Infect Microbiol* 2017, **7**:316.
272 ** Comprehnsive and excellent review describing how pathogenic, intracellular bacteria and
273 immune cells mutually modulate the metabolism. Together with reference 27, a complete
274 compendium of the state-of-the-art of the field.
275 2. Olive AJ, Sassetti CM: **Metabolic crosstalk between host and pathogen: sensing,**
276 **adapting and competing**. *Nat Rev Microbiol* 2016, **14**:221-234.
277 3. Escoll P, Buchrieser C: **Metabolic reprogramming of host cells upon bacterial**
278 **infection: Why shift to a Warburg-like metabolism?** *FEBS J* 2018.
279 4. Warburg O: **The metabolism of carcinoma cells**. *The Journal of Cancer Research* 1925,
280 **9**:148-163.
281 5. Koppenol WH, Bounds PL, Dang CV: **Otto Warburg's contributions to current**
282 **concepts of cancer metabolism**. *Nat Rev Cancer* 2011, **11**:325-337.
283 6. Ward PS, Thompson CB: **Metabolic reprogramming: a cancer hallmark even warburg**
284 **did not anticipate**. *Cancer Cell* 2012, **21**:297-308.
285 7. Appelberg R, Moreira D, Barreira-Silva P, Borges M, Silva L, Dinis-Oliveira RJ, Resende
286 M, Correia-Neves M, Jordan MB, Ferreira NC, et al.: **The Warburg effect in**
287 **mycobacterial granulomas is dependent on the recruitment and activation of**
288 **macrophages by interferon-gamma**. *Immunology* 2015, **145**:498-507.
289 8. Gleeson LE, Sheedy FJ, Palsson-McDermott EM, Triglia D, O'Leary SM, O'Sullivan MP,
290 O'Neill LA, Keane J: **Cutting Edge: *Mycobacterium tuberculosis* Induces Aerobic**
291 **Glycolysis in Human Alveolar Macrophages That Is Required for Control of**
292 **Intracellular Bacillary Replication**. *J Immunol* 2016, **196**:2444-2449.
293 9. Lachmandas E, Beigier-Bompadre M, Cheng SC, Kumar V, van Laarhoven A, Wang X,
294 Ammerdorffer A, Boutens L, de Jong D, Kanneganti TD, et al.: **Rewiring cellular**
295 **metabolism via the AKT/mTOR pathway contributes to host defence against**
296 **Mycobacterium tuberculosis in human and murine cells**. *Eur J Immunol* 2016,
297 **46**:2574-2586.
298 10. Shi L, Salamon H, Eugenin EA, Pine R, Cooper A, Gennaro ML: **Infection with**
299 ***Mycobacterium tuberculosis* induces the Warburg effect in mouse lungs**. *Sci Rep*
300 2015, **5**:18176.
301 11. Somashekar BS, Amin AG, Rithner CD, Troudt J, Basaraba R, Izzo A, Crick DC,
302 Chatterjee D: **Metabolic profiling of lung granuloma in *Mycobacterium***
303 ***tuberculosis* infected guinea pigs: ex vivo 1H magic angle spinning NMR studies**.
304 *J Proteome Res* 2011, **10**:4186-4195.
305 12. Escoll P, Song OR, Viana F, Steiner B, Lagache T, Olivo-Marin JC, Impens F, Brodin P,
306 Hilbi H, Buchrieser C: ***Legionella pneumophila* Modulates Mitochondrial**
307 **Dynamics to Trigger Metabolic Repurposing of Infected Macrophages**. *Cell Host*
308 *Microbe* 2017, **22**.
309 13. Czyz DM, Willett JW, Crosson S: ***Brucella abortus* Induces a Warburg Shift in Host**
310 **Metabolism That Is Linked to Enhanced Intracellular Survival of the Pathogen**. *J*
311 *Bacteriol* 2017, **199**.
312 14. Ojcius DM, Degani H, Mispelter J, Dautry-Varsat A: **Enhancement of ATP levels and**
313 **glucose metabolism during an infection by *Chlamydia.* NMR studies of living cells**.
314 *J Biol Chem* 1998, **273**:7052-7058.
315 15. Siegl C, Prusty BK, Karunakaran K, Wischhusen J, Rudel T: **Tumor suppressor p53**
316 **alters host cell metabolism to limit *Chlamydia trachomatis* infection**. *Cell Rep* 2014,
317 **9**:918-929.

318 16. Rupp J, Gieffers J, Klinger M, van Zandbergen G, Wrase R, Maass M, Solbach W,
319 Deiwick J, Hellwig-Burgel T: ***Chlamydia pneumoniae* directly interferes with HIF-**
320 **1alpha stabilization in human host cells**. *Cell Microbiol* 2007, **9**:2181-2191.
321 17. Everts B, Amiel E, Huang SC, Smith AM, Chang CH, Lam WY, Redmann V, Freitas TC,
322 Blagih J, van der Windt GJ, et al.: **TLR-driven early glycolytic reprogramming via**
323 **the kinases TBK1-IKKvarepsilon supports the anabolic demands of dendritic cell**
324 **activation**. *Nat Immunol* 2014, **15**:323-332.
325 18. Everts B, Amiel E, van der Windt GJ, Freitas TC, Chott R, Yarasheski KE, Pearce EL,
326 Pearce EJ: **Commitment to glycolysis sustains survival of NO-producing**
327 **inflammatory dendritic cells**. *Blood* 2012, **120**:1422-1431.
328 19. Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G,
329 Frezza C, Bernard NJ, Kelly B, Foley NH, et al.: **Succinate is an inflammatory**
330 **signal that induces IL-1beta through HIF-1alpha**. *Nature* 2013, **496**:238-242.
331 20. Palsson-McDermott EM, Curtis AM, Goel G, Lauterbach MA, Sheedy FJ, Gleeson LE,
332 van den Bosch MW, Quinn SR, Domingo-Fernandez R, Johnston DG, et al.: **Pyruvate**
333 **kinase M2 regulates Hif-1alpha activity and IL-1beta induction and is a critical**
334 **determinant of the warburg effect in LPS-activated macrophages**. *Cell Metab*
335 2015, **21**:65-80.
336 **Outstanding article that elegantly deciphers the role of PKM2 dimers and tetramers in the
337 regulation of the Warburg-like metabolism induced by LPS in macrophages, and its
338 consequence on infection with *Mycobacterium tuberculosis* or *Salmonella typhimurium*
339 21. Mills EL, Kelly B, Logan A, Costa ASH, Varma M, Bryant CE, Tourlomousis P, Dabritz
340 JHM, Gottlieb E, Latorre I, et al.: **Succinate Dehydrogenase Supports Metabolic**
341 **Repurposing of Mitochondria to Drive Inflammatory Macrophages**. *Cell* 2016,
342 **167**:457-470 e413.
343 22. Infantino V, Convertini P, Cucci L, Panaro MA, Di Noia MA, Calvello R, Palmieri F,
344 Iacobazzi V: **The mitochondrial citrate carrier: a new player in inflammation**.
345 *Biochem J* 2011, **438**:433-436.
346 23. Jha AK, Huang SC, Sergushichev A, Lampropoulou V, Ivanova Y, Loginicheva E,
347 Chmielewski K, Stewart KM, Ashall J, Everts B, et al.: **Network integration of**
348 **parallel metabolic and transcriptional data reveals metabolic modules that**
349 **regulate macrophage polarization**. *Immunity* 2015, **42**:419-430.
350 24. Michelucci A, Cordes T, Ghelfi J, Pailot A, Reiling N, Goldmann O, Binz T, Wegner A,
351 Tallam A, Rausell A, et al.: **Immune-responsive gene 1 protein links metabolism to**
352 **immunity by catalyzing itaconic acid production**. *Proc Natl Acad Sci U S A* 2013,
353 **110**:7820-7825.
354 25. Luan HH, Medzhitov R: **Food Fight: Role of Itaconate and Other Metabolites in**
355 **Antimicrobial Defense**. *Cell Metab* 2016, **24**:379-387.
356 26. Lampropoulou V, Sergushichev A, Bambouskova M, Nair S, Vincent EE, Loginicheva E,
357 Cervantes-Barragan L, Ma X, Huang SC, Griss T, et al.: **Itaconate Links Inhibition**
358 **of Succinate Dehydrogenase with Macrophage Metabolic Remodeling and**
359 **Regulation of Inflammation**. *Cell Metab* 2016, **24**:158-166.
360 27. Nair S, Huynh JP, Lampropoulou V, Loginicheva E, Esaulova E, Gounder AP, Boon
361 ACM, Schwarzkopf EA, Bradstreet TR, Edelson BT, et al.: **Irg1 expression in**
362 **myeloid cells prevents immunopathology during *M. tuberculosis* infection**. *J Exp*
363 *Med* 2018, **215**:1035-1045.
364 28. Lachmandas E, Boutens L, Ratter JM, Hijmans A, Hooiveld GJ, Joosten LA, Rodenburg
365 RJ, Fransen JA, Houtkooper RH, van Crevel R, et al.: **Microbial stimulation of**
366 **different Toll-like receptor signalling pathways induces diverse metabolic**
367 **programmes in human monocytes**. *Nat Microbiol* 2016, **2**:16246.

** Important article showing for the first time the heterogenous nature of metabolic responses of human primary monocytes to different TLR stimuli or whole-bacterial cell lysates.

29. Gillmaier N, Gotz A, Schulz A, Eisenreich W, Goebel W: **Metabolic responses of primary and transformed cells to intracellular *Listeria monocytogenes***. *PLoS One* 2012, **7**:e52378.
30. Stavru F, Bouillaud F, Sartori A, Ricquier D, Cossart P: **Listeria monocytogenes transiently alters mitochondrial dynamics during infection**. *Proc Natl Acad Sci U S A* 2011, **108**:3612-3617.
31. Eisenreich W, Heesemann J, Rudel T, Goebel W: **Metabolic host responses to infection by intracellular bacterial pathogens**. *Front Cell Infect Microbiol* 2013, **3**:24.
32. Saka HA, Valdivia RH: **Acquisition of nutrients by *Chlamydiae*: unique challenges of living in an intracellular compartment**. *Curr Opin Microbiol* 2010, **13**:4-10.
33. Hauslein I, Sahr T, Escoll P, Klausner N, Eisenreich W, Buchrieser C: ***Legionella pneumophila* CsrA regulates a metabolic switch from amino acid to glycerolipid metabolism**. *Open Biol* 2017, **7**.
34. Billig S, Schneefeld M, Huber C, Grassl GA, Eisenreich W, Bange FC: **Lactate oxidation facilitates growth of Mycobacterium tuberculosis in human macrophages**. *Sci Rep* 2017, **7**:6484.
35. Kim MJ, Wainwright HC, Locketz M, Bekker LG, Walther GB, Dittrich C, Visser A, Wang W, Hsu FF, Wiehart U, et al.: **Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism**. *EMBO Mol Med* 2010, **2**:258-274.
36. Singh V, Jamwal S, Jain R, Verma P, Gokhale R, Rao KV: ***Mycobacterium tuberculosis*-driven targeted recalibration of macrophage lipid homeostasis promotes the foamy phenotype**. *Cell Host Microbe* 2012, **12**:669-681.
37. Liu X, Lu R, Xia Y, Sun J: **Global analysis of the eukaryotic pathways and networks regulated by *Salmonella typhimurium* in mouse intestinal infection in vivo**. *BMC Genomics* 2010, **11**:722.
38. Ding K, Zhang C, Li J, Chen S, Liao C, Cheng X, Yu C, Yu Z, Jia Y: **cAMP Receptor Protein of *Salmonella enterica* Serovar Typhimurium Modulate Glycolysis in Macrophages to Induce Cell Apoptosis**. *Curr Microbiol* 2018.
39. Bowden SD, Rowley G, Hinton JC, Thompson A: **Glucose and glycolysis are required for the successful infection of macrophages and mice by Salmonella enterica serovar typhimurium**. *Infect Immun* 2009, **77**:3117-3126.
40. Sanman LE, Qian Y, Eisele NA, Ng TM, van der Linden WA, Monack DM, Weerapana E, Bogyo M: **Disruption of glycolytic flux is a signal for inflammasome signaling and pyroptotic cell death**. *Elife* 2016, **5**:e13663.

*Interesting paper showing how disruption of metabolic pathways by bacterial-induced piracy of nutrients leds to inflammasome activation.

41. Escoll P, Rolando M, Buchrieser C: **Modulation of Host Autophagy during Bacterial Infection: Sabotaging Host Munitions for Pathogen Nutrition**. *Front Immunol* 2016, **7**:81.
42. Martinez J, Verbist K, Wang R, Green DR: **The relationship between metabolism and the autophagy machinery during the innate immune response**. *Cell Metab* 2013, **17**:895-900.
43. Rathmell JC: **Metabolism and autophagy in the immune system: immunometabolism comes of age**. *Immunol Rev* 2012, **249**:5-13.
44. Harris J: **Autophagy and IL-1 Family Cytokines**. *Front Immunol* 2013, **4**:83.
45. Kunz TC, Viana F, Buchrieser C, Escoll P: **Manipulation of Autophagy by Bacterial Pathogens Impacts Host Immunity**. *Curr Issues Mol Biol* 2018, **25**:81-98.

46. Ogawa M, Yoshimori T, Suzuki T, Sagara H, Mizushima N, Sasakawa C: **Escape of intracellular *Shigella* from autophagy**. *Science* 2005, **307**:727-731.
47. Rolando M, Escoll P, Nora T, Botti J, Boitez V, Bedia C, Daniels C, Abraham G, Stogios PJ, Skarina T, et al.: **Legionella pneumophila S1P-lyase targets host sphingolipid metabolism and restrains autophagy**. *Proc Natl Acad Sci U S A* 2016, **113**:1901-1906.
48. Shin DM, Jeon BY, Lee HM, Jin HS, Yuk JM, Song CH, Lee SH, Lee ZW, Cho SN, Kim JM, et al.: ***Mycobacterium tuberculosis* eis regulates autophagy, inflammation, and cell death through redox-dependent signaling**. *PLoS Pathog* 2010, **6**:e1001230.
49. Tattoli I, Sorbara MT, Vuckovic D, Ling A, Soares F, Carneiro LA, Yang C, Emili A, Philpott DJ, Girardin SE: **Amino acid starvation induced by invasive bacterial pathogens triggers an innate host defense program**. *Cell Host Microbe* 2012, **11**:563-575.
50. Choy A, Dancourt J, Mugo B, O'Connor TJ, Isberg RR, Melia TJ, Roy CR: **The *Legionella* effector RavZ inhibits host autophagy through irreversible Atg8 deconjugation**. *Science* 2012, **338**:1072-1076.
51. Steele S, Brunton J, Kawula T: **The role of autophagy in intracellular pathogen nutrient acquisition**. *Front Cell Infect Microbiol* 2015, **5**:51.
52. Niu H, Xiong Q, Yamamoto A, Hayashi-Nishino M, Rikihisa Y: **Autophagosomes induced by a bacterial Beclin 1 binding protein facilitate obligatory intracellular infection**. *Proc Natl Acad Sci U S A* 2012, **109**:20800-20807.
53. Werth N, Beerlage C, Rosenberger C, Yazdi AS, Edelmann M, Amr A, Bernhardt W, von Eiff C, Becker K, Schafer A, et al.: **Activation of hypoxia inducible factor 1 is a general phenomenon in infections with human pathogens**. *PLoS One* 2010, **5**:e11576.
54. Wolf AJ, Reyes CN, Liang W, Becker C, Shimada K, Wheeler ML, Cho HC, Popescu NI, Coggeshall KM, Arditi M, et al.: **Hexokinase Is an Innate Immune Receptor for the Detection of Bacterial Peptidoglycan**. *Cell* 2016, **166**:624-636.
**Outstanding paper showing the immune surveillance function of the metabolic enzyme Hexokinase.
55. Pukkila-Worley R: **Surveillance Immunity: An Emerging Paradigm of Innate Defense Activation in Caenorhabditis elegans**. *PLoS Pathog* 2016, **12**:e1005795.

450 **Figure legends**

451

452 **Figure 1. General cellular metabolism (A) and the metabolic Warburg program (B).**
453 Large arrows and pathway names in bold represent increased metabolic fluxes. Anabolic
454 pathways appear in violet. Blue electron transport chain (ETC): active optimal OXPHOS;
455 pink ETC: reduced OXPHOS.

456

457 **Figure 2. Metabolic reprogramming of innate immune cells upon exposure to TLR4 or**
458 **TLR2 ligands. (A)** In DCs, TLR4 engagement by LPS increases glycolysis through the
459 activation of a TBK1-Akt-HK2 signalling axis. Glycolysis supplies DCs with citrate, which
460 fuels the synthesis of fatty acids that are required by activated DCs to increase their secretory
461 capacities. **(B)** In BMDM, LPS induces dimer and tetramer levels of PKM2. Increased PKM2
462 dimers lead to succinate accumulation and dimers also migrate to the nucleus, where they
463 induce IL1β transcription. LPS-induction of PKM2 tetramers increases the rate of glycolysis.
464 A broken TCA cycle leads to OXPHOS reduction and succinate and citrate accumulation.
465 Accumulated succinate stabilizes HIF1α that can be translocated to the nucleus and drive
466 IL1β gene expression. In mitochondria, succinate oxidation leads to mROS production and
467 subsequent HIF1α-mediated IL1β mRNA expression. Accumulated citrate is used to generate
468 NO, ROS and prostaglandins by BMDMs, as well as to produce the antimicrobial metabolite
469 itaconate. **(C)** Human monocytes shift to a Warburg-like metabolism when stimulated with
470 LPS, but not upon stimulation with the TLR2 ligand P3C. In P3C-stimulated monocytes,
471 increased glycolysis is accompanied by increased OXPHOS. Elevated succinate, itaconate
472 and citrate levels were observed in LPS-stimulated but not in P3C-stimulated monocytes.

473

474 **Figure 3. Metabolic reprogramming of host cells infected by intracellular bacteria. (A)**
475 *Salmonella enterica* serovar Typhimurium (*St*) diverts glucose to the bacterial vacuole, while
476 *Chlamydia spp.* (*Chl*) induce the Pentose Phosphate Pathway (PPP) to produce nucleotides for
477 bacterial replication. **(B)** *Legionella pneumophila* (*Lp*) induces glycolysis, reduces OXPHOS,
478 and might take advantage of this metabolism to acquire amino acids from the host cell. **(C)**
479 *Mycobacterium tuberculosis* (*Mtb*) induces glycolysis, reduces OXPHOS, and increase fatty
480 acids synthesis to use lipid bodies and glycolytic-generated lactate as nutrients for its own
481 growth.

482


A
Glycolysis
OXPHOS
Glucose
2ATP
Pyruvate
Lactate
ETC
36ATP
TCA
B
Glycolysis
OXPHOS
Glucose
PPP
2ATP
Lipid
and Nucleotide
synthesis
Pyruvate
Lactate
Amino acid
and Fatty acid
synthesis
ETC
TCA


A
TBK1
TLR4
LPS
IKKε
Akt
HK2
Glucose
Glycolysis
Pyruvate
Lactate
Citrate
OXPHOS
Fatty acid synthesis
B
HIF1α
IL1β mRNA
LPS
TLR4
HIF1α
Succinate
PKM2
Glucose
Glycolysis
Lactate
mROS
Pyruvate
PKM2
Citrate
NO and itaconate synthesis
OXPHOS
C
NO and itaconate synthesis
LPS
TLR4
OXPHOS
Citrate
Succinate
Glucose
Glycolysis
Pyruvate
OXPHOS
TLR2
P3C
Lactate


A
Glucose
St
Glucose
PPP
Glycolysis
Nucleotide synthesis
Pyruvate
Chl
B
Glucose
Glycolysis
Lp
?
Amino acid synthesis
Pyruvate
OXPHOS
Lactate
C
Glucose
Glycolysis
Mtb
Pyruvate
Fatty acid synthesis
OXPHOS
Lactate